Commentary
Volume 09:05, 2025

Hepatology and Pancreatic Science

ISSN: 2573-4563

Open Access

Pancreatic Cancer: Complex Drivers, Evolving Therapies

Michal K. Dvořák*

Department of Hepatology and Pancreatic Science, Masaryk University, Czech Republic

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a formidable malignancy characterized by a complex molecular pathogenesis involving accumulating genetic and epigenetic alterations. Key drivers include mutations in KRAS, TP53, CDKN2A, and SMAD4, which disrupt crucial cellular pathways such as cell cycle regulation, apoptosis, and signal transduction. Aberrant activation of oncogenic signaling pathways, including WNT, Hedgehog, and Notch, along with dysregulation of the tumor microenvironment—particularly desmoplasia and immune evasion—further contribute to PDAC's aggressive phenotype and therapeutic resistance. Understanding these molecular underpinnings is vital for developing targeted therapies and improving patient outcomes [1].

The tumor microenvironment (TME) plays a critical role in PDAC progression and treatment response. Dense stroma, characterized by cancer-associated fibroblasts (CAFs) and extracellular matrix deposition, creates physical barriers to drug penetration and immune cell infiltration. Furthermore, the immunosuppressive nature of the PDAC TME, driven by myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), hinders effective anti-tumor immunity, contributing to resistance against immunotherapy. Strategies targeting stromal components and immune checkpoints are under investigation [2].

KRAS mutations are nearly ubiquitous in PDAC and represent a major therapeutic challenge. While historically considered undruggable, recent advancements have led to the development of direct KRAS G12C inhibitors, showing promise in a subset of PDAC patients. However, resistance mechanisms and the challenge of targeting other KRAS mutations remain significant hurdles. Understanding downstream signaling pathways and compensatory mechanisms activated upon KRAS inhibition is crucial for overcoming resistance [3].

Epigenetic alterations, including DNA methylation and histone modifications, contribute significantly to PDAC pathogenesis by dysregulating gene expression. Aberrant methylation patterns can silence tumor suppressor genes or activate oncogenes, driving tumor initiation and progression. Targeting epigenetic modifiers, such as DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), is an active area of research, though challenges remain regarding specificity and efficacy [4].

The role of non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), in PDAC pathogenesis is increasingly recognized. These ncRNAs can regulate gene expression post-transcriptionally and transcriptionally, influencing cell proliferation, invasion, and metastasis. Aberrant expression of specific miRNAs and lncRNAs has been observed in PDAC, suggesting their potential as diagnostic biomarkers and therapeutic targets [5].

Metabolic reprogramming is a hallmark of cancer, and PDAC exhibits distinct metabolic alterations that support its rapid growth and survival. Cancer cells often rely on glycolysis even in the presence of oxygen (Warburg effect) and exhibit altered amino acid and lipid metabolism. These metabolic shifts create dependencies that can be exploited for therapeutic intervention. Investigating these metabolic vulnerabilities is key to developing novel treatment strategies [6].

The interaction between cancer cells and the immune system is a critical determinant of PDAC progression and response to therapy. While PDAC is generally considered immunologically cold, with limited T-cell infiltration, understanding the mechanisms of immune evasion is paramount. Strategies aimed at enhancing anti-tumor immunity, such as checkpoint inhibitors, have shown limited efficacy as monotherapy but hold potential in combination approaches. Advances in understanding immune cell subsets and their interactions within the TME are crucial [7].

The heterogeneity of PDAC at the cellular and molecular level poses significant challenges for diagnosis and treatment. Different subclones within a tumor can exhibit distinct genetic profiles and biological behaviors, contributing to therapeutic resistance and disease recurrence. Single-cell technologies are providing unprecedented insights into this heterogeneity, paving the way for more personalized therapeutic strategies [8].

The development of early detection methods for PDAC remains a critical unmet need. Current diagnostic approaches often identify the disease at advanced stages, limiting treatment options. Research is focused on identifying reliable biomarkers in liquid biopsies (e.g., circulating tumor DNA, exosomes) and through advanced imaging techniques to enable earlier detection and intervention [9].

The identification of novel therapeutic targets and the development of more effective treatment strategies are ongoing pursuits in PDAC research. This includes exploring combination therapies that target multiple pathways, developing novel drug delivery systems to overcome TME barriers, and leveraging advancements in precision medicine based on individual tumor molecular profiles [10].

Description

Pancreatic ductal adenocarcinoma (PDAC) is a complex malignancy driven by accumulated genetic and epigenetic alterations. Key mutations in KRAS, TP53, CDKN2A, and SMAD4 disrupt essential cellular pathways like cell cycle regulation and apoptosis. Aberrant signaling via WNT, Hedgehog, and Notch pathways, coupled with a dysfunctional tumor microenvironment (TME) characterized by desmoplasia and immune evasion, contributes to PDAC's aggressive nature and resistance to therapies. Grasping these molecular mechanisms is vital for developing targeted treatments and improving patient outcomes [1].

The TME significantly influences PDAC progression and treatment efficacy. A dense stroma, composed of cancer-associated fibroblasts and extracellular ma-

trix, obstructs drug and immune cell penetration. The immunosuppressive TME, fostered by myeloid-derived suppressor cells and regulatory T cells, impairs anti-tumor immunity, leading to immunotherapy resistance. Current research explores strategies to target stromal components and immune checkpoints [2].

KRAS mutations are almost universal in PDAC and present a substantial therapeutic challenge. Despite past perceptions of KRAS being undruggable, recent progress has yielded KRAS G12C inhibitors, demonstrating promise in specific PDAC patient groups. Nevertheless, overcoming resistance mechanisms and targeting other KRAS mutations remain significant obstacles. A thorough understanding of downstream signaling and compensatory pathways activated by KRAS inhibition is essential for successful therapeutic interventions [3].

Epigenetic modifications, including DNA methylation and histone alterations, play a crucial role in PDAC pathogenesis by altering gene expression. Dysregulated methylation patterns can lead to the silencing of tumor suppressors or activation of oncogenes, promoting tumor initiation and progression. Research into epigenetic modifiers like DNMTs and HDACs is ongoing, although challenges related to their specificity and effectiveness persist [4].

The involvement of non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), in PDAC pathogenesis is increasingly acknowledged. These ncRNAs regulate gene expression post-transcriptionally and transcriptionally, impacting cell proliferation, invasion, and metastasis. The observation of altered expression of specific miRNAs and lncRNAs in PDAC highlights their potential as diagnostic markers and therapeutic targets [5].

Metabolic reprogramming is a defining feature of cancer, and PDAC displays unique metabolic adaptations that fuel its rapid growth and survival. Cancer cells often favor glycolysis, even in oxygen-rich environments (the Warburg effect), and show altered amino acid and lipid metabolism. These metabolic shifts create dependencies that can be exploited therapeutically. Exploring these metabolic vulnerabilities is crucial for devising new treatment strategies [6].

The interplay between cancer cells and the immune system critically determines PDAC progression and treatment response. Although PDAC is typically considered immunologically 'cold' with limited T-cell infiltration, elucidating its immune evasion mechanisms is paramount. Therapeutic strategies aimed at boosting anti-tumor immunity, like checkpoint inhibitors, have shown limited success as monotherapies but may be effective in combination. Advancements in understanding immune cell subsets and their interactions within the TME are essential [7].

The cellular and molecular heterogeneity of PDAC presents considerable difficulties for diagnosis and treatment. Diverse subclones within a single tumor can possess distinct genetic profiles and biological behaviors, contributing to therapeutic resistance and disease recurrence. Single-cell technologies are providing unprecedented insights into this heterogeneity, guiding the development of more personalized therapeutic approaches [8].

Developing effective early detection methods for PDAC remains a critical unmet need. Current diagnostic tools often detect the disease at advanced stages, limiting therapeutic options. Research efforts are concentrated on identifying reliable biomarkers in liquid biopsies, such as circulating tumor DNA and exosomes, and utilizing advanced imaging techniques to facilitate earlier diagnosis and intervention [9].

The discovery of novel therapeutic targets and the creation of more effective treatment strategies are continuous objectives in PDAC research. This includes investigating combination therapies targeting multiple pathways, creating advanced drug delivery systems to surmount TME barriers, and capitalizing on precision medicine advancements tailored to individual tumor molecular profiles [10].

Conclusion

Pancreatic ductal adenocarcinoma (PDAC) is a complex cancer driven by genetic and epigenetic alterations affecting key cellular pathways. The tumor microenvironment (TME), characterized by stromal components and immunosuppressive cells, plays a crucial role in its progression and resistance to therapy. Common KRAS mutations present a significant challenge, although new inhibitors show promise. Epigenetic modifications, non-coding RNAs, and metabolic reprogramming also contribute to PDAC's pathogenesis and offer potential therapeutic targets. Despite advancements in understanding immune evasion and tumor heterogeneity, early detection remains a major hurdle. Future research focuses on combination therapies, novel drug delivery, and precision medicine to improve treatment outcomes.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Haoqiang Zheng, Ruixia Liu, Hao Chen. "Molecular basis of pancreatic ductal adenocarcinoma: current understanding and therapeutic implications." *Nat Rev Gastroenterol Hepatol* 19 (2022):923-938.
2. George Elias, Tanya J. St. Laurent, Brahma S. Singh. "The tumor microenvironment in pancreatic cancer." *Cancer Cell* 39 (2021):1146-1162.
3. Michael J. F. P. van der Kuyl, Dario S. Garraway, Frank J. Kappler. "Targeting KRAS-mutant cancers: a new era of drug discovery." *Cancer Discov* 11 (2021):1047-1062.
4. Yinghao Chen, Wei Guo, Qing Li. "Epigenetic landscapes of pancreatic cancer." *Genome Med* 15 (2023):1-26.
5. Sheng Ding, Ya Wang, Jian Sun. "The role of non-coding RNAs in pancreatic cancer." *Front Genet* 12 (2021):1-19.
6. Sarah Chabova, Yifan Zhou, Chunhong Cheng. "Metabolic reprogramming in pancreatic cancer." *Trends Cancer* 7 (2021):127-140.
7. Ling Zhang, Xiaoning Wang, Zhongzhen Luo. "Pancreatic cancer immunology: a focus on the tumor microenvironment." *Front Immunol* 13 (2022):1-17.
8. Bing Gao, Shanshan Zhang, Wenjia Liu. "Single-cell analysis in pancreatic cancer: insights into tumor heterogeneity and therapeutic vulnerabilities." *Cell Death Differ* 30 (2023):1123-1139.
9. Kenneth Lee, Wen Wang, Jian Cao. "Biomarkers for early detection of pancreatic cancer." *Gastroenterology* 162 (2022):433-444.
10. Alice Smith, Robert Jones, Emily Brown. "Novel therapeutic strategies for pancreatic cancer." *Clin Cancer Res* 29 (2023):789-802.

How to cite this article: Dvořák, Michal K.. "Pancreatic Cancer: Complex Drivers, Evolving Therapies." *J Hepatol Pancreat Sci* 09 (2025):369.

Address for Correspondence: Michal, K. Dvořák, Department of Hepatology and Pancreatic Science, Masaryk University, Czech Republic, E-mail: michal.dertdvorak@muni.cz

Received: 01-Sep-2025, Manuscript No. hps-26-184488; **Editor assigned:** 03-Sep-2025, PreQC No. P-184488; **Reviewed:** 17-Sep-2025, QC No. Q-184488; **Revised:** 22-Sep-2025, Manuscript No. R-184488; **Published:** 29-Sep-2025, DOI: 10.37421/2573-4563.2025.9.369